Opinion|Videos|June 19, 2024
Eculizumab Impact on PNH Treatment Landscape and Unmet Needs in PNH Management
Medical experts highlight unmet needs in the PNH treatment landscape and considerations for utilizing eculizumab.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Eculizumab was the first-in-class complement C5 inhibitor for PNH. Can you elaborate on the mechanism of action of eculizumab and its impact on the management of PNH?
- Please elaborate on the persistent unmet needs in PNH management, such as residual intravascular hemolysis and C3-mediated extravascular hemolysis. How do they contribute to the treatment burden for patients?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
The True Cost of Running a Community CAR T-Cell Program
2
Bringing CAR T-Cell Therapy Into Community Cancer Centers
3
Tozorakimab Cuts COPD Exacerbations Up to 34% in Phase 3 Trials
4
Texas Hospitals Lose $27 Million a Day in Medicaid Funding Dispute
5